Back to articles

Revolutionary Gene Editing Delivers New Hope for Sickle Cell and Beta Thalassemia

Amelia Hernandez•Jun 12, 2025
A microscopic view of a targeted lipid nanoparticle precisely delivering CRISPR gene editing tools to a hematopoietic stem cell, with a subtle glow indicating successful editing of the DNA within, against a backdrop of healthy red blood cells.
  • Milan Breakthrough: Editas Medicine stuns at EHA 2025, revealing potent preclinical success for in vivo gene editing in non-human primates.
  • Historic Editing Levels: A single dose achieved an unprecedented 58% on-target editing in hematopoietic stem cells (HSCs), far exceeding the 25% threshold deemed necessary for therapeutic impact in sickle cell disease and beta thalassemia [6, 8].
  • Precision Delivery: Proprietary targeted lipid nanoparticle (tLNP) technology demonstrated remarkable accuracy, hitting HSCs while significantly avoiding the liver, a major leap for safety and efficacy6.

In the heart of Milan, at the European Hematology Association 2025 Congress, a wave of excitement surges as Editas Medicine (Nasdaq: EDIT) unveils data that could redefine the fight against inherited blood disorders [1, 5]. The company presented compelling new evidence from non-human primate studies, showcasing its pioneering in vivo gene editing approach for sickle cell disease and beta thalassemia – conditions that have long cast shadows over countless lives.

The data, presented on June 12th and detailed further on June 14th, reveals that a single intravenous administration of Editas's proprietary tLNP system successfully delivered CRISPR/Cas12a gene editing machinery directly to HSCs. Five months post-treatment, these cells showed a mean on-target editing level of 58% at the HBG1/2 promoters6. This elegant strategy aims to reactivate fetal hemoglobin (HbF) production, mimicking a natural genetic variation (HPFH) that protects individuals from disease symptoms. Achieving levels well above the 25% therapeutic benchmark with a single dose marks a pivotal moment8.

Crucially, Editas's tLNP system demonstrated a favorable biodistribution, significantly de-targeting the liver compared to standard LNPs, addressing a key challenge in gene therapy delivery6. "These data from our HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs," stated Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer at Editas Medicine.

This preclinical triumph, building on the clinical validation of promoter editing seen with reni-cel, signals a potential paradigm shift: moving from complex ex vivo procedures to a more accessible in vivo treatment. As Editas Medicine (www.editasmedicine.com) continues to translate the power of CRISPR gene editing, these findings light a path towards transformative, durable medicines for patients worldwide, offering a profound new sense of hope [7, 8].

References

  1. ehaweb.org
  2. ehaweb.org
  3. news.vrtx.com
  4. ir.editasmedicine.com
  5. www.biospace.com
  6. www.stocktitan.net
  7. www.globenewswire.com
  8. www.globenewswire.com

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.